Previous close | 120.60 |
Open | 121.00 |
Bid | 122.80 x 0 |
Ask | 122.80 x 0 |
Day's range | 121.00 - 123.00 |
52-week range | 91.00 - 124.40 |
Volume | |
Avg. volume | 982 |
Market cap | 311.563B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 146.43 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.84 (2.31%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.